The other reason why the broad-spectrum immunomodulator, Lp-PLA2 inhibitor, and p38 MAPK kinase inhibitor showed no benefits in CHD patients is that the involved patients are not enough in quantity. This evidence concerns the gene PLA2G7 and coronary artery disorder.